Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 3/20 | 0.47 |
| ▸ | SYK | P43405 | 12/20 | 0.42 |
| ▸ | ULK1 | O75385 | 4/20 | 0.37 |
| ▸ | BMX | P51813 | 2/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | ITK | Q08881 | 2/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | STK25 | O00506 | 1/20 | 0.36 |
| ▸ | CIT | O14578 | 1/20 | 0.36 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | MUSK | O15146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744556 | 0.93 | PRKCQ (0.47) | PRKCQSYKULK1BMXBTK | |
| SCHEMBL1743613 | 0.91 | PRKCQ (0.58) | PRKCQSYKULK1BMXBTK | |
| SCHEMBL17082793 | 0.87 | PRKCQ (0.48) | PRKCQSYKULK1BMXBTK | |
| SCHEMBL1744909 | 0.86 | PRKCQ (0.43) | PRKCQSYKULK1BMXBTK | |
| SCHEMBL1744598 | 0.86 | PRKCQ (0.47) | PRKCQSYKULK1BMXBTK | |
| SCHEMBL1744518 | 0.83 | PRKCQ (0.57) | PRKCQSYKULK1BMXBTK | |
| SCHEMBL15322379 | 0.83 | PRKCQ (0.44) | PRKCQSYKULK1BMXBTK | |
| SCHEMBL15322695 | 0.83 | PRKCQ (0.44) | PRKCQSYKULK1BMXBTK | |
| SCHEMBL15320749 | 0.83 | PRKCQ (0.44) | PRKCQSYKULK1BMXBTK | |
| SCHEMBL1740448 | 0.83 | PRKCQ (0.60) | PRKCQSYKBTKEGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453028-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | claimed |
| US-20150376203-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2015-12-31 | — | — | US | claimed |
| US-8394951-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS INC. (US) | 2013-03-12 | — | — | US | claimed |
| EP-2387572-A2 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | claimed |
| US-8040334-B2 | Method of driving display device | 02MICRO INTERNATIONAL LIMITED (KY) | 2011-10-18 | — | — | US | claimed |
| WO-2010083207-A2 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | claimed |
| US-20100184755-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-07-22 | — | — | US | claimed |
| EP-3046560-B1 | STEM CELL MODULATION II | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-01-06 | — | — | EP | disclosed |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| CN-111587120-A | Immunogenic compositions and uses thereof | 艾比克斯治疗私人有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-10736892-B2 | Stem cell modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190192509-A1 | Stem Cell Modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-06-27 | — | — | US | disclosed |
| US-9095593-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130143875-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8394951-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2387572-A2 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040334-B2 | Method of driving display device | 02MICRO INTERNATIONAL LIMITED (KY) | 2011-10-18 | — | — | US | disclosed |
| WO-2010083207-A2 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100184755-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736892-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885SYK 2245/4885ULK1 1303/4885 |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | NFATC1, PRKCQ, PRKCH | PRKCQ 2/4885SYK 1306/4885ULK1 341/4885 |
| US-20150376203-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | PRKCQ 5/4885SYK 600/4885ULK1 282/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885SYK 2047/4885ULK1 884/4885 |
| US-20130143875-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | PRKCQ 5/4885SYK 600/4885ULK1 282/4885 |
| US-20190192509-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885SYK 2245/4885ULK1 1303/4885 |
| US-20100184755-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | PRKCQ 5/4885SYK 600/4885ULK1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.